Catalyst Wire Dossier Catalyst Wire Dossier

ARX-F01 Sublingual Sufentanil

sufentanil · Talphera, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARX-F01 Sublingual Sufentanil, covering 2015-01-22 to 2015-01-22. Get the full timeline:

Most recent: Clinical Trial Update: A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery [Phase 2]

See pricing